ALLO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Allogene Therapeutics (ALLO) is a good buy for a beginner long-term investor with $50,000-$100,000 available, and my clear view is to buy it now. The stock has a strong catalyst-backed setup after positive ALPHA3 interim data, analyst targets have moved sharply higher, and the company now has runway into Q1 2029. For an impatient investor, the current price around 2.23 still looks like a reasonable entry rather than waiting for a perfect pullback.
MACD is positive and expanding, RSI is elevated but not a sell signal, and price is trading just below the first resistance level, indicating a bullish but somewhat stretched setup.
Positive ALPHA3 interim data, analyst target hikes, bullish options flow, cash runway into Q1 2029, and an orderly CEO succession.
CEO transition, higher operating cash expense guidance, near-term resistance, and some short-term overextension.
Q1 2026 showed a small EPS beat at -$0.18 versus expectations, with runway extending into Q1 2029 and 2026 cash burn guidance around $165 million.
Analysts have turned more bullish after ALPHA3 data, with several target increases to the $8-$12 range and mostly Buy/Outperform ratings; JPMorgan upgraded to Neutral from Underweight, reflecting improved sentiment but not unanimous conviction.
